New β-lactam-β-lactamase inhibitor combinations in clinical development

Annals of the New York Academy of Sciences

Volumn 1277, Issue 1, 2013, Pages 105-114

  Shlaes, David M ^a  

^a Anti Infectives Consulting   (United States)

Author keywords

Beta lactam beta lactamase inhibitor combinations; Beta lactamase; Clinical development

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AVIBACTAM; AVIBACTAM PLUS CEFTAROLINE; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; BETA LACTAMASE TEM 1; CARBAPENEM; CARBAPENEMASE; CEFTAROLINE; CEFTAZIDIME; CEFTOLOZANE; CEFTOZOLANE PLUS TAZOBACTAM; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CILASTATIN PLUS IMIPENEM PLUS MK 7655; METRONIDAZOLE; MK 7655; PIPERACILLIN PLUS TAZOBACTAM; RPX 7009; TAZOBACTAM; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; DEACYLATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; ENTEROBACTERIACEAE; ENZYME INHIBITION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HUMAN; HYDROLYSIS; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTION;

EID: 84872844727     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12010     Document Type: Article

References (44)

1. Bulik, C.C., P.R. Tessier, R.A. Keel, et al. 2012. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob. Agents Chemother. 56: 544-549.
2. Bush, K. & J.F. Fisher 2011. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu. Rev. Microbiol. 65: 455-478.
3. Drawz, S.M. & R.A. Bonomo 2010. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23: 160-201.
4. Bush, K., C. Macalintal, B.A. Rasmussen, et al. 1993. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37: 851-588.
5. Coleman, K. 2011. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr. Opin. Microbiol. 14: 550-555.
6. Kuzin, A., M. Nukaga, Y. Nukaga, et al. 2001. Inhibition of the SHV-1 B-lactamase by sulfones: crytallographic observation of two reaction intermediates. Biochemical 40: 1861-1868.
7. Hirsch, E.B., K.R. Ledesma, K.T. Chang, et al. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob. Agents Chemother. 56: 3753-3757.
8. Castanheira, M., O. Lomovskaya, P.R. Rhomberg & R.N. Jones 2012. Activity of RPX2003/RPX7009, a carbapenem combined with a novel B-lactamase inhibitor tested against clinical isolates product defined enzymes. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract F-855.
9. Sader, H.S., M. Castanheira, D.J. Farrell & R.N. Jones 2010. Antimicrobial activity of ceftazidime/NXL-104 tested against Gram negative organisms including multidrug-resistant subsets, causing infections in USA and European mecial centers. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract E-811.
10. Stachyra, T., M.C. Péchereau, J.M. Bruneau, et al. 2010. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob. Agents Chemother. 54: 5132-5138.
11. Young, K.L., S.L. Raghoobar, N.N. Hairston, et al. 2010. In vitro activity of the class A and class C B-lactamase inhibitor MK-7655. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting Abstract F1-2139.
12. Ehmann, D.E., H. Jahic, P.L. Ross, et al. 2012. Avibactam is a covalent, reversible, non-B-lactam B-lactamase inhibitor. Proc. Natl. Acad. Sci. USA 109: 11663-11668.
13. Young, K., M. Hackel, C. Lascols, et al. 2012. Response to Imipenem plus MK-7655, a novel β-lactamase inhibitor, in a surveillance study population of P. aeruginosa from SMART 2009. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract C2-724.
14. Komuro, M., T. Maeda, H. Kakuo, et al. 1994. Inhibition of the renal excretion of tazobactam by piperacillin. J. Antimicrob. Chemother. 34: 555-564.
15. Rice, L.B., E.C. Eckstein, J. DeVente & D.M. Shlaes 1996. Ceftazidime-resistant Klebsiellapneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin. Infect. Dis. 23: 118-124.
16. Sirot, D., C. Recule, E.B. Chaibi, et al. 1997. Complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob. Agents Chemother. 41: 1322-1325.
17. Yang, Y., B.A. Rasmussen & D.M. Shlaes 1999. Class A beta-lactamases-enzyme-inhibitor interactions and resistance. Pharmacol. Ther 83: 141-151.
18. Bonomo, R.A., S.A. Rudin & D.M. Shlaes 1997. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases. FEMS Microbiol. Lett. 148: 59-62.
19. Cabot, G., M.D. Macià, M. Gozalo, et al. 2010. Activity of CXA-101 against a large collection of P. aeruginosa blood stream isolates overexpressing AmpC and the major efflux pumps. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract E-816.
20. Badal, R., S. Bouchillon, M. Hackel, et al. 2010. Impact of NXL-104 on ceftaroline MICs for bacteria producing extended spectrum, AmpC or KPC B-lactamases. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract E-804.
21. Castanheira, M., P.R. Rhomberg, R.N. Jones & D.J. Farrell 2010. Potent activity of ceftazidime/NXL-104 against Enterobactereaceae isolates carrying multiple B-lactamase enzymes. ECCMID Annual Meeting, Abstract 1265.
22. Queenan, A. M. & K. Bush 2007. Carbapenemases: the versatile lactamases. Clin. Microbiol. Rev. 20: 440-458.
23. Titelman, E., I.M. Karlsson, Y. Ge & C.G. Giske 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis 70: 137-141.
24. Sader, H.S., P.R. Rhomberg, D.J. Farrell & R.N. Jones 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. 55: 2390-2394.
25. Sader, H.S., R.K. Flamm, J.M. Streit & R.N. Jones 2012. Activity of the novel antimicrobial ceftolozane/tazobactam tested against contemporary clinical strains from USA hospitals (2011). 52ndInterscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting Abstract E-199.
26. Castanheira, M., H.S. Sader, D.J. Farrell, R.E. Mendes, R.N. Jones 2012. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various SCCmec types. Antimicrob. Agents Chemother. 56: 4779-4785.
27. Walkty, A., M. DeCorby, P.R. Lagac, et al. 2011. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob. Agents Chemother. 55: 2992-2994.
28. Rizk, M.L., G.F. Ahmed, K. Young, et al. 2012. A semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model for MK-7655, a novel β-lactamase inhibitor (BLI) for use in combination with imipenem/cilastatin. 52nd Interscience Conference on Antimicrobial Agents and ChemotherapyAnnual Meeting, Abstract A-1763.
29. Flamm, R.K., W. Nichols, H. Sader & R.N. Jones 2012. Avibactam reverts the MIC90 of a recent set of European clinical isolates of Gram negative bacteria back to the epidemiological cutoff value. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract E-187.
30. Sader, H.S., R.K. Flamm, J.M. Streit & R.N. Jones 2012. Activity of ceftaroline-avibactam against contemporary clinical isolates from USA medical centers. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract E186.
31. Livermore, D.M., M. Warner & S. Mushtaq 2012. Activity of MK-7655 with imipenem vs.β-lactamase producers. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract E-192.
32. Livermore, D.M., S. Mushtaq, K. Barker, et al. 2012. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J. Antimicrob. Chemother. 67: 1354-1358.
33. Borgonovi, M., H. Merdjan, A.M. Girard, et al. 2008. Importance of NXL-104 pharmacokinetics in the pharmacodynamics of ceftazidime-NXL-104 combinations. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract A-023.
34. Nichols, W., P. Levasseur & S. Das 2012. A threshold concentration of avibactam during the pharmacokinetic decline ph52nd ase, below which B-lactamase inhibition in Enterobacteriaceae becomes ineffective. Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract A-1760.
35. Schuck, V., M. Tanudra, M.E. Beaudoin, et al. 2012. In vivo efficacy of simulated human exposures of cetazidime-avibactam against Pseudomonas aeruginosa in a hollow fiber model. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract A-632.
36. Louie, A., M. Castanheira, W. Liu, et al. 2012. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob. Agents Chemother. 56: 258-270.
37. Mushtaq, S., M. Warner, Y. Ge, et al. 2007. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60: 300-311
38. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract F1-2142.
39. Umeh, O., D. Cebrik & I.R. Friedland 2010. A double-blind randomized phase 2 study to compare the safety and efficacy of intravenous CXA-101 and intravenous ceftazidime in complicated urinary tract infection. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract L1-361A.
40. Lucasti, C., I. Popescu, M. Ramesh, et al. 2010. Efficacy and safety of ceftazidimeavibactam (ceftazidime/NXL-104) plus metronidazole versus meropenem in the treatment of complicated intraabdominal infections in hospitalized adults. ECCMID Annual Meeting Abstract 1532.
41. Vasquez, J.A., L.D.G. Patzan, J. Lipka & C. Sable 2010. Efficacy, safety and tolerability of ceftazidimeavibactam (ceftazidime/NXL-104) versus imipenemcilastatin in the treatment of complicated urinary tract infections in hospitalized adults. ECCMID Annual Meeting, Abstract 1533.
42. Hecker, S.J., K.R. Reddy, M. Totrov, et al. 2012. Discovery of RPX7009, a borad spectrum B-lactamase inhibnitor with utility vs. class A serine carbapenemases. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract F-848.
43. Lomovskaya, O., P. King, D. Sun, et al. 2012. Microbiological characterization of the B-lactamase inhibitor RPX7009. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, Abstract F-850.
44. Livermore, D.M., S. Mushtaq, M. Warner, et al. 2011. Activities of NXL-104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents and Chemother. 55: 390-394.